These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15780823)

  • 21. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
    Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
    Mavri A; Alessi MC; Juhan-Vague I
    J Intern Med; 2004 Apr; 255(4):448-56. PubMed ID: 15049879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lifestyle modification and endothelial function in obese subjects.
    Hamdy O
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
    Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
    Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches.
    Nordt TK; Bode C
    Semin Thromb Hemost; 2000; 26(5):495-501. PubMed ID: 11129405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease.
    Després JP
    J Endocrinol Invest; 2006; 29(3 Suppl):77-82. PubMed ID: 16751711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human visceral adipose tissue and the plasminogen activator inhibitor type 1.
    Lindeman JH; Pijl H; Toet K; Eilers PH; van Ramshorst B; Buijs MM; van Bockel JH; Kooistra T
    Int J Obes (Lond); 2007 Nov; 31(11):1671-9. PubMed ID: 17471294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of adiponectin in obesity, diabetes, and cardiovascular disease.
    Kawano J; Arora R
    J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adipokines in diabetes and cardiovascular diseases.
    Kralisch S; Sommer G; Deckert CM; Linke A; Bluher M; Stumvoll M; Fasshauer M
    Minerva Endocrinol; 2007 Sep; 32(3):161-71. PubMed ID: 17912155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
    Schernthaner GH; Schernthaner G
    Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Review of the cooperative study of Veterans' affairs on the control and complications of type 2 diabetes, especially cardiovascular diseases].
    Nuttall FQ
    Journ Annu Diabetol Hotel Dieu; 1998; ():99-112. PubMed ID: 9773613
    [No Abstract]   [Full Text] [Related]  

  • 34. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing risk across the spectrum of patients with the metabolic syndrome.
    Rosenson RS
    Am J Cardiol; 2005 Aug; 96(4A):8E-10E. PubMed ID: 16098836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.
    Yamamoto K; Takeshita K; Kojima T; Takamatsu J; Saito H
    Cardiovasc Res; 2005 May; 66(2):276-85. PubMed ID: 15820196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.